Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Richard Dimelow"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 4, Pp 462-473 (2023)
Abstract Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by B‐cell hyperactivity and breach of tolerance. Autoreactive memory B cells, which have a decreased activation threshold and the ability to survive in absence of an
Externí odkaz:
https://doaj.org/article/757f986ec1034a9a83e9e39cfda175c6
Autor:
Sang-Cheol Bae, Damon L. Bass, Myron Chu, Paula Curtis, Richard Dimelow, Laurence Harvey, Beulah Ji, Regina Kurrasch, Saima Muzaffar, Raj Punwaney, David A. Roth, Yeong-Wook Song, Wendy Xie, Fengchun Zhang
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-11 (2022)
Abstract Background Treatment goals for patients with systemic lupus erythematosus (SLE) include minimising disease activity and reducing the risk of flares. Although belimumab is effective at reducing disease activity and risk of severe flares, it w
Externí odkaz:
https://doaj.org/article/ff6acac1a96a455ebd7f0d19e3d58275
Publikováno v:
Clinical Pharmacology in Drug Development
The phase 2 placebo‐controlled, double‐blind PLUTO trial characterized the pharmacokinetics of belimumab plus standard systemic lupus erythematosus (SLE) therapy in patients with childhood‐onset SLE (cSLE) and demonstrated similar efficacy and
Autor:
Sang-Cheol Bae, Damon L. Bass, Myron Chu, Paula Curtis, Richard Dimelow, Laurence Harvey, Beulah Ji, Regina Kurrasch, Saima Muzaffar, Raj Punwaney, David A. Roth, Yeong-Wook Song, Wendy Xie, Fengchun Zhang
Publikováno v:
Arthritis researchtherapy. 24(1)
Background Treatment goals for patients with systemic lupus erythematosus (SLE) include minimising disease activity and reducing the risk of flares. Although belimumab is effective at reducing disease activity and risk of severe flares, it was previo
Publikováno v:
Drugs in R&D
DRUGS IN R&D
DRUGS IN R&D
Objectives Our objective was to develop population pharmacokinetic (PK) models for ceftazidime and avibactam in the plasma and epithelial lining fluid (ELF) of healthy volunteers and to compare ELF concentrations to plasma PK/pharmacodynamic (PD) tar
Autor:
Annamaria, Bevilacqua, Stephen J, Wilkinson, Richard, Dimelow, Ettore, Murabito, Samrina, Rehman, Maria, Nardelli, Karen, van Eunen, Sergio, Rossell, Frank J, Bruggeman, Nils, Blüthgen, Dirk, De Vos, Jildau, Bouwman, Barbara M, Bakker, Hans V, Westerhoff
Publikováno v:
SEB experimental biology series. 61
Autor:
Annamaria Bevilacqua, Wilkinson, Stephen J., Richard Dimelow, Ettore Murabito, Samrina Rehman, Maria Nardelli, Karen van Eunen, Sergio Rossell, Bruggeman, Frank J., Nils Blüthgen, Dirk De Vos, Jildau Bouwman, Bakker, Barbara M., Westerhoff, Hans V.
Publikováno v:
University of Manchester-PURE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f04f7754bee6e451de99f7c0196776f4
https://ir.cwi.nl/pub/16285
https://ir.cwi.nl/pub/16285